Reduce Turnaround Time For Global Oncology Clinical Trials

End-to-end anatomic pathology and histology solutions and the power of biomarkers combine to reduce turnaround time for global oncology clinical trials.

Drug development challenges exist on multiple fronts: finding enough patients to recruit for global clinical trials; operating under greater regulatory and commercial pressures; delivering against more stringent expectations from healthcare providers and patients. How do successful companies navigate through this barrage of demands to achieve a quality submission?